A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients
-
Uma A. Bhosale
,
Nilofar Quraishi
Abstract
Background: During the past 2 years, a great deal of evaluation has been accomplished on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs), nonselective and selective cyclooxygenase-2 inhibitors (COX-2-Is). Clinical trial databases for nonselective and selective COX-2-Is have shown variable effects on CV risk. There is much controversy regarding the CV safety of these selective and nonselective COX inhibitors (COX-Is). This study was therefore conducted to assess and compare the CV risk of COX-Is in arthritic patients over a period of time.
Methods: In this prospective comparative study, adult arthritics of either sex who were freshly diagnosed or taking COX-Is for <3 months were included. Patients were grouped into nonselective and selective COX-2-I groups with reference to the treatment they received, whereas arthritics with no history of COX-I treatment were included as controls. CV risk factors like blood pressure (BP), blood sugar level (BSL), lipid profile, and body mass index (BMI) were assessed and compared; the demography of CV risk factors was also studied. Data obtained were analyzed with Student’s t-test using OpenEpi statistical software (Andrew G. Dean and Kevin M. Sullivan, Atlanta, GA, USA).
Results: The study clearly revealed that all NSAIDs exhibit potential CV risk; however, selective COX-2-Is were found to exhibit more CV risk. BMI, BP and lipid profile, the potential CV risk factors, showed significant impairment in a selective COX-2-I group: p<0.01, p<0.001 and p<0.05, respectively, vs. baseline and p<0.05 for BMI and triglycerides vs. nonselective COX-Is.
Conclusions: This study depicts the impending CV risk of selective COX-2-Is and confirms and reevaluates the results of earlier studies in this regard.
Acknowledgments
The authors are thankful to Dr. A.V. Bhore, Dean, Smt. Kashibai Navale Medical College (SKNMC), Dr. Madhav Khadilkar, Head of Department (HOD) Orthopaedics, and Dr. Dnyaneshwari Ghadage Central Clinical Laboratory (CCL) in-charge (I/C) for providing facilities to carry out the experiments in this work.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Ritter JM, Harding I, Warren JB. Precaution, cyclooxygenase inhibition, and cardiovascular risk. Trends Pharmacol Sci 2009;30:503–8.10.1016/j.tips.2009.07.007Search in Google Scholar
2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520–8.10.1056/NEJM200011233432103Search in Google Scholar
3. Silverstein FE, Faich G, Goldstein JL, Simon JS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. J Am Med Assoc 2000;284:1247–55.10.1001/jama.284.10.1247Search in Google Scholar
4. Weir MR, Sperling RS, Reicin A, Gertz BJ. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 2003;146:591–604.10.1016/S0002-8703(03)00398-3Search in Google Scholar
5. Crofford LJ, McDonagh KT, Schmaier AH, Oates JC. Cyclooxygenase 2 inhibitors and thrombogenicity production: comment on the article by Crofford et al. [letter]. Arthritis Rheum 2001;44:1229–30.Search in Google Scholar
6. Ehrich EW, Dallob A, de Lepeleire I, van Hecken A, Riendeau D, Yuan W. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65: 336–47.10.1016/S0009-9236(99)70113-XSearch in Google Scholar
7. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001;286:954–9.10.1001/jama.286.8.954Search in Google Scholar
8. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280–8.10.1161/hc4401.100078Search in Google Scholar
9. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068–73.10.1161/01.CIR.0000127578.21885.3ESearch in Google Scholar
10. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus nonselective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based comparative study. Lancet 2004;363:1751–6.10.1016/S0140-6736(04)16299-5Search in Google Scholar
11. Hootman JM, Helmick CG, Brady TJ. A public health approach to addressing arthritis in older adults: the most common cause of disability. Am J Public Health 2012;102:426–33.10.2105/AJPH.2011.300423Search in Google Scholar PubMed PubMed Central
12. Kuo CF, Luo SF, See LC, Chou IJ, Chang HC, Yu KH. Rheumatoid arthritis prevalence, incidence, and mortality rates: a nationwide population study in Taiwan. Rheumatol Int 2013;33:355–60.10.1007/s00296-012-2411-7Search in Google Scholar
13. Irons BK, Snella KA, McCall K, MacLaughlin EJ, Villarreal M. Update on the management of dyslipidemia. Am J Health-Syst Pharm 2002;59:1615–25.10.1093/ajhp/59.17.1615Search in Google Scholar
14. Topol EJ. Failing the public health – rofecoxib, Merck, and the FDA. N Engl J Med 2004;351:1707–9.10.1056/NEJMp048286Search in Google Scholar
15. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharm Pharm Sci 2004;7:332–6.Search in Google Scholar
16. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet 2004;364: 675–84.10.1016/S0140-6736(04)16894-3Search in Google Scholar
17. Mackenzie IS, Wei L, MacDonald TM. Cardiovascular safety of lumiracoxib: a meta-analysis of randomized controlled trials in patients with osteoarthritis. Eur J Clin Pharmacol 2013;69: 133–41.10.1007/s00228-012-1335-1Search in Google Scholar
18. Giorgi M, Kim TW, Saba A, Rouini MR, Yun H, Ryschanova R, et al. Detection and quantification of cimicoxib, a novel COX-2 inhibitor, in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. J Pharm Biomed Anal 2013;83:28–33.10.1016/j.jpba.2013.04.024Search in Google Scholar
19. Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, et al. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study). Rheumatology (Oxford) 2009;48:425–32.10.1093/rheumatology/kep005Search in Google Scholar
20. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al.; MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771–81.10.1016/S0140-6736(06)69666-9Search in Google Scholar
21. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086.10.1136/bmj.c7086Search in Google Scholar PubMed PubMed Central
22. Gross GJ, Falck JR, Gross ER, Isbell M, Moore J, Nithipatikom K. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited. Cardiovasc Res 2005;68:18–25.10.1016/j.cardiores.2005.06.007Search in Google Scholar PubMed
23. Qi Z, Hao CM, Langenbach RI, Breyer RM, Redha R, Morrow JD, et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest 2002;110:61–9.10.1172/JCI0214752Search in Google Scholar
24. Grosser T, Smyth EM, FitzGerald GA. Anti-inflammatory, antipyretic and analgesic agents; pharmacotherapy of gout. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gillman’s the pharmacological basics of therapeutics, 12th ed. China: McGraw Hill, 2011:962–76.Search in Google Scholar
25. Ealsh MF, Pek SB. Effects of lipoxygenase and cyclooxygenase inhibitors on glucose-stimulated insulin secretion from the isolated perfused rat pancreas. Life Sci 1984, 34:1699–706.10.1016/0024-3205(84)90567-8Search in Google Scholar
26. TMT Review: Cardiovascular safety of Celebrex. Available at www.fda.gov/ohrms/dockets/dockets/04n0559/04N-0559. Accessed on December 2013.Search in Google Scholar
27. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. Circulation 2005;112:941–5.10.1161/CIRCULATIONAHA.105.567842Search in Google Scholar PubMed
28. Agarwal DP. Cardioprotective effects of light–moderate consumption of alcohol: a review of putative mechanisms. Alcohol Alcohol 2002;37:409–15.10.1093/alcalc/37.5.409Search in Google Scholar PubMed
©2015 by De Gruyter
Articles in the same Issue
- Frontmatter
- Review
- Cell cycle checkpoints and pathogenesis of HIV-1 infection: a brief overview
- Behavior/Neuroprotection
- Neuroprotective effect of N-acetyl cysteine against streptozotocin-induced memory dysfunction and oxidative damage in rats
- Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery
- Involvement of opioidergic and serotonergic systems in the analgesic activity of Cissus quadrangularis L. stem extract in mice
- Multiparameter rodent chronic model for complex evaluation of alcoholism-mediated metabolic violations
- Reproduction
- The methanol-soluble fraction of Millettia macrophylla (Fabaceae) stem bark endowed with estrogenic properties has adverse effects on the male reproductive system of Wistar rats
- Cardiovascular Function
- Kolaviron, a biflavonoid fraction from Garcinia kola, protects against isoproterenol-induced injury by mitigating cardiac dysfunction and oxidative stress in rats
- A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients
- Metabolism
- Increased levels of serum γ-glutamyltransferase and uric acid on metabolic, hepatic and kidney parameters in subjects at high altitudes
- Phytotherapy
- Anti-inflammatory and antinociceptive activities of the aqueous leaf extract of Phyllanthus amarus Schum (Euphorbiaceae) in some laboratory animals
- Gastroprotective activity of essential oils from turmeric and ginger
- Decreased metabolism of 13C-caffeine via hepatic CYP1A2 in marasmus and kwashiorkor based on breath test
Articles in the same Issue
- Frontmatter
- Review
- Cell cycle checkpoints and pathogenesis of HIV-1 infection: a brief overview
- Behavior/Neuroprotection
- Neuroprotective effect of N-acetyl cysteine against streptozotocin-induced memory dysfunction and oxidative damage in rats
- Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery
- Involvement of opioidergic and serotonergic systems in the analgesic activity of Cissus quadrangularis L. stem extract in mice
- Multiparameter rodent chronic model for complex evaluation of alcoholism-mediated metabolic violations
- Reproduction
- The methanol-soluble fraction of Millettia macrophylla (Fabaceae) stem bark endowed with estrogenic properties has adverse effects on the male reproductive system of Wistar rats
- Cardiovascular Function
- Kolaviron, a biflavonoid fraction from Garcinia kola, protects against isoproterenol-induced injury by mitigating cardiac dysfunction and oxidative stress in rats
- A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients
- Metabolism
- Increased levels of serum γ-glutamyltransferase and uric acid on metabolic, hepatic and kidney parameters in subjects at high altitudes
- Phytotherapy
- Anti-inflammatory and antinociceptive activities of the aqueous leaf extract of Phyllanthus amarus Schum (Euphorbiaceae) in some laboratory animals
- Gastroprotective activity of essential oils from turmeric and ginger
- Decreased metabolism of 13C-caffeine via hepatic CYP1A2 in marasmus and kwashiorkor based on breath test
